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EDITORIAL 
We are particularly excited about this Special Issue of OPO in that this is the first Feature 
Edition specifically dedicated to glaucoma. Clinical translation in research involves turning 
discoveries into health and each of us, as Associate Editors, work in countries where a 
significant change of direction has been observed in recent years, with much more of a focus 
on developing measurable improvements in patient’s health. Examples of the large numbers 
of projects and investment related to glaucoma include that the National Institute for Health 
Research, the research arm of the National Health Service, where there are currently 
(January 2015) 161 active Ophthalmology studies, 23 (14%) of which are related to 
glaucoma, while in the United States of America, the National Eye Institute lists 447 projects 
relating to glaucoma with a total funding of $172 million. 
The original articles in this issue cover the full spectrum from laboratory to clinical research 
that includes information on community and hospital-based glaucoma care. Basic research 
articles include a number of ‘firsts’. Of the laboratory research, two studies relate to ocular 
blood flow and function.   O’Connell et al elevated the IOP of young human healthy 
volunteers to about 30 mmHg to test the autoregulatory response in terms of blood flow but 
also retinal function. Raising the IOP to this level did not decrease retinal blood flow, 
suggesting that this IOP was within the limits of autoregulation.  However, the rise in IOP did 
reduce venous oxygen saturation and altered retinal function (reduced pattern 
electroretinogram), suggesting that the neurons are indeed stressed by mild IOP elevation. 
Using a diabetic rat model, Wong et al report that chronic IOP elevation further reduces the 
capacity of diabetic eyes to autoregulate ocular blood flow against IOP elevation. Relating to 
blood flow but within the clinical setting, Kuerten et al reported a significant and sustained 
increase in retrobubar blood flow velocity after trabeculectomy in 30 primary open angle 
glaucoma patients, where IOP had dropped by approx. 60% compared to pre-surgery 
values. For readers interested in blood flow, this study’s discussion offers a very 
comprehensive review of the literature and interactions between measures of blood flow, 
autoregulation and perfusion pressure. 
Among glaucoma patients, Pescosolido et al performed a small study on patients on 
maximally tolerated medical therapy for POAG by treating with a melatonin agonist, 
agomelatine orally, as part of their routine psychiatric treatment for mood disorders. This is 
the first time this has been used in humans with glaucoma despite good evidence for its use 
in animal models. A 30% decrease in IOP from the enrolment pressure up to a month after 
treatment was observed and these findings may prompt further development of agomelatine 
for topical application. 
Chong et al present an interesting study involving targeted spatial sampling (GOANNA) to 
detect visual field progression. This method tests more spatial locations (3 degree intervals 
rather than 6) than the standard 24-2 grid but with the same test time, and exhibited more 
accurate classification of progressing visual fields compared with conventional ZEST (Zippy 
Estimation by Sequential Testing), especially in early stages of progression. The spatial 
interdependency of false responses is an interesting factor to consider when developing next 
generation procedures like GOANNA, where locations are chosen autonomously during the 
test. 
 
Stepping into the clinic, Campbell et al report on the agreement between various methods of 
anterior chamber angle assessment by comparing intra-observer agreement van Herick, 
Ocular Coherence Tomograph and gonioscopy. Despite being the ‘gold standard’, 
gonioscopy fared poorly in terms of repeatability. The van Herick method was shown to have 
good sensitivity and specificity for detection of occludable angles and the particular OCT 
device they evaluated had poor sensitivity yet high specificity. Jindal et al focus specifically 
on the van Herick technique and report inter-observer agreement between optometrists an 
ophthalmologists concluding that the augmented 7-point % grading scale is intuitive and 
potentially offers greater accuracy for grading narrow angles than the traditional 4-point 
scale for grading limbal anterior chamber depth.  
 
Nowomiejska et al challenge us to think ‘outside the box’ whether that box be a 24 or 30 
degree visual field! They present a fascinating study involving semi-automated kinetic 
perimetry that provides additional information to static automated perimetry in the 
assessment of the remaining visual field in end-stage glaucoma. Two further studies shine a 
light on the burden of glaucoma in different age groups affected by glaucoma. Gupta et al 
report a 10% lifetime risk of perimetric blindness in juvenile open-angle glaucoma patients 
aged 10-40 years. This subgroup of our glaucoma population presents important challenges 
to us, such as the tendency to present with higher intraocular pressures and the impact of 
the disease on the social and economic productivity of this age group. Boodhna et al note 
that in predominantly adult-onset glaucoma, severity of vision loss at the point of glaucoma 
detection is improving over time in England. Taking a gigantic dataset of visual fields (almost 
half a million VF from almost 100,000 patients!), average visual field loss became less 
severe over 13 year follow-up period. The study emphasises the fact that many patients with 
glaucoma continue to present to eyecare specialists when disease is at an advanced stage 
(a fifth had advanced visual field loss in at least one eye). The authors recommend that 
incentivising the use of available visual field technology and using it more appropriately in 
primary care is more important than chasing ‘preperimetric’ glaucoma with newer 
technologies. 
 To conclude, we hope the readership will be inspired by the breadth of articles in this special 
Feature Edition which demonstrate the drive to better understand the causes and effects of 
glaucoma. These reports demonstrate that the detection and treatment of glaucoma, the 
Worlds leading cause of irreversible blindness, is improving and we hope that this issue will 
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